< Back to Schedule

Parallel Session: NAFLD and NASH: Therapeutics

Sunday, November 15
10:30 am
12:00 pm


No items found.

About the Session

Watch this live session to see some the top research in NAFLD and NASH. Content will only be aired on this date, at this time. Don't miss it!

  • Novel, First-in-Class, Fatty Acic Synthase (FASN) Inhibitor, TVB-2640 Demonstrates Clinically Significant Reduction in Liver Fat by MRI-PDFF, and ALT in NASH: A Phase 2 Randomized Placebo-Controlled Trial (FASCINATE-1)
    Presenting Author Rohit Loomba
  • Statin Use is Associated with Reduced Cancer-Related Mortality Among Patients with Non-Alcoholic Fatty Liver Disease: A National Prosepctive Cohort Study
  • Hyperhomocysteinemia is a Marker and Mediator of NASH: Discovery of a Novel Vitamin Therapy (B12 and Folate) for NASH
    Presenting Madhulika Tripthai
  • Evaluation of Obeticholic Acid Efficacy in Patients with NASH who were Monitored Using Noninvasive Tests: A Post Hoc Analyiss of the Regnerate Trial
    Presenting Author Naim Alkhouri
  • Mitochondrial SAB (SH3BP5) is a Novel Target for Anisense Oligonucleotide (ASO) Treatment in Experiemental NASH and Fibrosis
    Presenting Author Sanda Win
  • Final Analysis of a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aldafermin (NGM282) In Patients with Nonalcoholic Steatohepatitis
    Presenting Author Stephen Harrison